Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Epicrispr gene silencer is 1st drug to boost muscle in form of muscular dystrophy, biotech says
(18h)
Biogen ends Apellis research programs, cuts ‘small number’ of roles after $5.6B buyout
(19h)
Moderna enters in vivo CAR-T, granting autoimmune asset ‘007’ license to kill pathogenic cells
(20h)
BioPharma Dive
At BIO, tension over China biotech deal regulation looms
(17h)
Alkermes’ incoming CEO has a plan to outplay Lilly and Takeda
(19h)
On second try, Acadia drug gets nod from European regulators
(19h)
Endpoints News
FDA approves Viridian eye drug, stoking competition with Amgen's Tepezza
(10h)
FDA advisory panels are back, with new meetings for Replimune, Capricor
(14h)
Akeso pushes back on ASCO questioning of lung cancer drug
(17h)
BioSpace
Capricor thrown for another loop as FDA sets adcomm for DMD cardiomyopathy therapy
(13h)
BIO 2026: Making biotech IPOs great again and the forgotten pharma antitrust review
(19h)
The hidden cost of FDA unpredictability
(19h)
STAT News
BIO 2026: AI, federal policy impacts, and general vibes
(15h)
Up and down the ladder: The latest comings and goings
(17h)
988’s LGBTQ+ hotline to relaunch this year. But the group that helped start it might be excluded
(18h)
BioPharma Trend
Seven HealthTech Trends In Europe To Watch
(18h)
Self-Care Is Not a Product, It’s Critical Infrastructure: Why We Must Work Together to Make Health Systems Resilient.
(1w)
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio launch ADME-One, a packaged ADME service for hit identification
(1mo)
Drug Channels
BlinkRx Insights: The Questions Manufacturers Wish They Had Asked Before Selecting a Patient Services Partner
(22h)
Pharmacist Salaries and Employment in 2025: Retail Declines, Hospital Gains
(4d)
The Digital Front Door to Specialty Therapy May Not Be a Specialty Pharmacy
(1w)
European Biotechnology Magazine
ProQR validates RNA editing platform and raises $59.2m
(1d)
Recordati secures ex-U.S. rights to Ionis’ Alexander disease therapy
(1d)
ADC Therapeutics cuts 17% of staff after safety setback
(2d)
Drug Hunter
May 2026
(13h)
MRTX1719
(1d)
cleminorexton
(2d)
Labiotech.EU
“It’s time to Act”: EU biotech to undergo major changes
(19h)
De-risking neurology drug development with better mouse models
(1d)
How human-first datasets are reshaping AI drug discovery
(2d)
Bio IT World
The Spatial Biology Bottleneck: Why AI Models Fail on Complex Tissue & What Actually Fixes It
(1d)
Every Microbiome Tells a Changeable, Computable Story
(3d)
Notes from the Trenches: A Computational Biologist’s View of Drug Discovery’s Digital Revolution
(4d)
GEN News
Backed by $165M, Bionyra Pharma Launches to Advance Inflammatory Disease Biologics
(13h)
Genome Editing at the Turning Point—Bringing CRISPR to Clinical Reality
(16h)
Intravesical CAR T-Cell Therapy Reduces Bladder Cancer Growth in Preclinical Model
(16h)
Cure Today
Without Cancer I Am Practicing Self-Care
(1d)
FDA Approves Trodelvy Alone or With Keytruda for First-Line Triple-Negative Breast Cancer
(2d)
The Whole Person: How Susan Yaguda Is Redefining Cancer Care
(2d)
Contract Pharma
Reducing Risk in Pharma Product Transfers
(15h)
Adragos Pharma Kawagoe, Towa Pharmaceutical Ink Strategic Supply Pact
(17h)
AI in Biologics CDMO Workflows: A BIO Conversation with Lonza
(17h)
Pharma Times
Racura treats first patient in phase 1 HARNESS‑1 lung cancer trial
(2d)
NICE recommends MSD’s pembrolizumab for locally advanced cervical cancer
(2d)
Lundbeck to present new Vyepti and bocunebart data at EAN 2026
(2d)
Medcity News
What Is AI Getting Right — and Wrong — in Healthcare’s Revenue Cycle?
(1w)
KFF: Insurer Participation in ACA Marketplaces Is Down
(1w)
FDA Reversal on uniQure Gene Therapy Is Another Sign of Renewed Regulatory Flexibility
(1w)
Chemical & Engineering News
Supreme Court sides with Bayer in landmark pesticide-labeling case
(13h)
A new method measures PFAS-based microplastics
(15h)
Policy Watch: HHS moves to keep more drug trials in the US
(16h)
The Pharma Letter
Why has the need in gMG become so severe, and how has understanding evolved?
(16h)
EC opens formal antitrust investigation on Sanofi
(16h)
June 2026 batch of EMA/CHMP recommendations
(16h)
Targeted Oncology
NCCN Guidelines Recommend ctDNA-MRD Testing in MIBC Care
(1d)
Emerging Evidence for Earlier Intervention in Low-Risk Polycythemia Vera
(2d)
Why Many Oncologists Still Reach for G-CSF Over Trilaciclib in ES-SCLC
(2d)
MedWatch
Hims & Hers poised to benefit as insurers pull back on weight-loss drug coverage
(20h)
Demant on track for best quarter since the turn of the millennium
(21h)
GN Hearing CFO to join Danish shipping company
(22h)
In The Pipeline
Speaking Up: Who Is, and Who Isn't
(11h)
Antibody-Drug Conjugates: Not Quite Worked Out Yet
(1d)
Here's a Ligand, Go Design a Protein
(2d)
Pharmaphorum
Sanofi faces EU investigation over flu shot marketing
(21h)
Moderna shows in vivo CAR-T hand in R&D update
(22h)
Obesity is rising fastest in young adults in England
(1d)
Drug Discovery Weekly
Wegovy pill could help patients lose 17% body weight
(1w)
How AskBio is pioneering ‘transformative genetic therapies’ in Parkinson’s disease
(1w)
Webinar: Learn how to accelerate the early stages of drug discovery
(1w)
HIT Consultant
KLAS Arch Collaborative Releases Clinician EHR Experience 2026 Impact Report
(18h)
Hera Raises $27M to Scale AI-Powered Senior Care Coordination
(18h)
ZS Impact Institute Releases 2026 Future of Health Report: AI and the Consumer-Led Care Revolution
(19h)
Insights: Pink Sheet
US Pushing Foreign Countries To Pay More For Drugs: Will It Help Americans?
(10h)
BsUFA IV: Money Can’t Buy Industry Reference Product Exclusivity Determinations
(12h)
US FDA Adcomm Will Review Formerly Rejected Capricor, Replimune Regenerative Medicines
(14h)
BioXconomy
AI cannot fix oncology drug discovery when preclinical models fail to reflect patient tumor biology
(12h)
Saudi drug authority expands US partnerships
(18h)
Clinilabs partners with Rutgers clinical research training
(20h)
BioCentury
Immunic tests Nurr1 to push beyond MS’s inflammation ceiling
(7h)
House committee to vote on China investment and in-licensing restrictions
(9h)
Definium’s $805M offering leads follow-on quartet: Public Equity Report
(9h)
SCRIP
Viridian’s Lumvoa Puts Pressure On Amgen’s Tepezza In TED
(9h)
BIO 2026: Deals Are Surging Even As Chinese Competition And MFN Concerns Linger
(10h)
Callio Makes The Case For Dual-Payload ADCs
(13h)